An accelerated design, combined, prospective ascending single-dose and two-dose, randomised, placebo-controlled, blinded, first-in-human adaptive study in healthy adults and patients with COVID-19 infection, to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody AOD01
- Funded by National Medical Research Council Singapore
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
National Medical Research Council SingaporePrincipal Investigator
A/Prof. Chien and David Boon and LyeResearch Location
SingaporeLead Research Institution
NCID (TTSH)Research Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Phase 1 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase I
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified